Lenzilumab治疗COVID-19肺炎住院患者(LIVE-AIR):一项3期随机安慰剂对照试验
LIVE-AIR是一项3期随机双盲安慰剂对照试验,纳入美国与巴西29个中心无需有创机械通气的COVID-19肺炎住院成人,1:1随机接受lenzilumab 600 mg每剂静脉给药共3剂(间隔8小时)或安慰剂,均接受包括瑞德西韦和糖皮质激素在内的标准支持治疗。主要终点为改良意向治疗人群28天无有创机械通气生存,lenzilumab组198例(84%;95% CI 79-89)vs 安慰剂组190例(78%;72-83)达到,lenzilumab组生存可能性更高(HR 1.54;95% CI 1.02-2.32;p=0.040)。lenzilumab组255例中68例(27%)vs 安慰剂组257例中84例(33%)发生至少1次CTCAE≥3级不良事件,最常见为呼吸系统疾病(26%)和心脏疾病(6%),均未导致死亡。作者结论为lenzilumab显著改善无有创机械通气生存且安全性类似安慰剂,但其在糖皮质激素及其他免疫调节剂之外的附加价值仍未知。
要点
- 无需有创机械通气的COVID-19肺炎住院成人,lenzilumab组28天无有创机械通气生存198/236(84%;95% CI 79-89)vs 安慰剂组190/243(78%;72-83),HR 1.54(95% CI 1.02-2.32;p=0.040)。
- 方案为lenzilumab 600 mg每剂静脉给药共3剂、间隔8小时,或安慰剂,均联合包括瑞德西韦和糖皮质激素在内的标准支持治疗。
- CTCAE≥3级不良事件lenzilumab组68/255(27%)vs 安慰剂组84/257(33%),最常见为呼吸系统疾病(26%)和心脏疾病(6%),均未导致死亡。
- 作者结论:lenzilumab疗效显著、安全性类似安慰剂,但其在糖皮质激素及其他COVID-19免疫调节剂之外的附加价值仍未知。
适用人群与场景
- 美国与巴西29个中心收治的COVID-19肺炎住院成人,不需要有创机械通气。
- 改良意向治疗人群(mITT)为接受至少1剂研究药物并在主要研究者或助理研究者监督下给药的随机参与者,共479例(lenzilumab组236例、安慰剂组243例)。
- 安全性分析纳入所有接受至少1剂研究药物的患者(lenzilumab组255例、安慰剂组257例)。
处置流程与药物剂量
- lenzilumab组:静脉给予lenzilumab 600 mg每剂,共3剂,每剂间隔8小时。
- 安慰剂组:按相同给药方案给予安慰剂。
- 所有患者均接受标准支持治疗,包括使用瑞德西韦和糖皮质激素;449例(94%)使用糖皮质激素,347例(72%)使用瑞德西韦,331例(69%)两者均用。
- 随机化时按年龄和疾病严重程度分层。
研究设计与关键结果
- 研究类型:3期随机双盲安慰剂对照试验;29个中心(美国与巴西);2020年5月5日至2021年1月27日入组;筛查528例,随机520例纳入意向治疗人群,479例纳入mITT主要分析。
- 基线:男性311例(65%),平均年龄61岁(SD 14),C反应蛋白中位数79 mg/L(IQR 41-137)。
- 主要终点:28天无有创机械通气生存,lenzilumab组198/236(84%;95% CI 79-89)vs 安慰剂组190/243(78%;72-83);lenzilumab组生存可能性更高(HR 1.54;95% CI 1.02-2.32;p=0.040)。
- 不良事件:CTCAE≥3级不良事件lenzilumab组68/255(27%)vs 安慰剂组84/257(33%);最常见的≥3级治疗中出现的不良事件为呼吸系统疾病(26%)和心脏疾病(6%),均未导致死亡。
证据类型、等级与局限
- 证据类型:3期随机双盲安慰剂对照试验。
- 作者结论:lenzilumab显著改善无需有创机械通气的COVID-19住院患者的无有创机械通气生存,安全性特征与安慰剂相似;lenzilumab在糖皮质激素及其他用于治疗COVID-19的免疫调节剂之外的附加价值仍未知。
对床旁实践的改变
- 作者认为,对于无需有创机械通气的COVID-19肺炎住院成人,在标准支持治疗(包括瑞德西韦和糖皮质激素)基础上加用lenzilumab可显著改善28天无有创机械通气生存(84% vs 78%,HR 1.54,p=0.040),安全性类似安慰剂。
- 作者指出,lenzilumab在糖皮质激素及其他用于治疗COVID-19的免疫调节剂之外的附加价值仍未知。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19 beyond available treatments.
METHODS: In LIVE-AIR, a phase 3, randomised, double-blind, placebo-controlled trial, hospitalised adult patients with COVID-19 pneumonia not requiring invasive mechanical ventilation were recruited from 29 sites in the USA and Brazil and were randomly assigned (1:1) to receive three intravenous doses of lenzilumab (600 mg per dose) or placebo delivered 8 h apart. All patients received standard supportive care, including the use of remdesivir and corticosteroids. Patients were stratified at randomisation by age and disease severity. The primary endpoint was survival without invasive mechanical ventilation to day 28 in the modified intention-to-treat population (mITT), comprising all randomised participants who received at least one dose of study drug under the documented supervision of the principal investigator or sub-investigator. Adverse events were assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04351152, and is completed.
FINDINGS: Patients were enrolled from May 5, 2020, until Jan 27, 2021. 528 patients were screened, of whom 520 were randomly assigned and included in the intention-to-treat population. 479 of these patients (n=236, lenzilumab; n=243, placebo) were included in the mITT analysis for the primary outcome. Baseline demographics were similar between groups. 311 (65%) participants were males, mean age was 61 (SD 14) years at baseline, and median C-reactive protein concentration was 79 (IQR 41-137) mg/L. Steroids were administered to 449 (94%) patients and remdesivir to 347 (72%) patients; 331 (69%) patients received both treatments. Survival without invasive mechanical ventilation to day 28 was achieved in 198 (84%; 95% CI 79-89) participants in the lenzilumab group and in 190 (78%; 72-83) patients in the placebo group, and the likelihood of survival was greater with lenzilumab than placebo (hazard ratio 1·54; 95% CI 1·02-2·32; p=0·040). 68 (27%) of 255 patients in the lenzilumab group and 84 (33%) of 257 patients in the placebo group experienced at least one adverse event that was at least grade 3 in severity based on CTCAE criteria. The most common treatment-emergent adverse events of grade 3 or higher were related to respiratory disorders (26%) and cardiac disorders (6%) and none led to death.
INTERPRETATION: Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with COVID-19, with a safety profile similar to that of placebo. The added value of lenzilumab beyond other immunomodulators used to treat COVID-19 alongside steroids remains unknown.
参考来源
- Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021. PMID: 34863332. doi:10.1016/S2213-2600(21)00494-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。